Hsbc Holdings PLC Buys 35,902 Shares of Ralliant Corporation $RAL

Hsbc Holdings PLC lifted its position in shares of Ralliant Corporation (NYSE:RAL) by 230.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,500 shares of the company’s stock after purchasing an additional 35,902 shares during the quarter. Hsbc Holdings PLC’s holdings in Ralliant were worth $2,627,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RAL. Cetera Investment Advisers purchased a new stake in shares of Ralliant in the 2nd quarter worth about $700,000. Russell Investments Group Ltd. purchased a new position in Ralliant during the 2nd quarter valued at about $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in Ralliant in the second quarter worth about $39,000. First Trust Advisors LP purchased a new stake in Ralliant in the second quarter worth about $2,013,000. Finally, Federated Hermes Inc. bought a new stake in shares of Ralliant in the 2nd quarter worth approximately $326,000.

Ralliant Trading Up 0.1%

Shares of NYSE:RAL opened at $72.24 on Monday. The stock’s 50-day simple moving average is $58.13 and its two-hundred day simple moving average is $51.25. The stock has a market capitalization of $8.09 billion and a price-to-earnings ratio of -6.60. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million during the quarter. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts expect that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is currently -1.83%.

Analysts Set New Price Targets

RAL has been the topic of several analyst reports. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Truist Financial reaffirmed a “buy” rating and issued a $68.00 price target (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Royal Bank Of Canada upped their price target on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 13th. Oppenheimer increased their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Finally, TD Cowen raised their price objective on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ralliant currently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.